Drug Trial Radar · NCT06667908
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Dec 6, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
JNJ-90301900Drug
JNJ-90301900 will be injected intratumorally and/or intranodally.
DurvalumabBiological
Durvalumab will be administered as intravenous (IV) infusion as cIT.
Concurrent Chemo/Radiation Therapy (cCRT)Radiation
Radiation by intensity modulated radiation therapy (IMRT) will be administered.
Concurrent Chemo/Radiation Therapy (cCRT): CarboplatinDrug
Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.
Concurrent Chemo/Radiation Therapy (cCRT): PaclitaxelDrug
Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Using Independent Central Review (ICR) AssessmentTime frame: Up to 2 Years and 2 months
Locations
45 sites in 10 countries. Site status is shown where the registry gives one.
Moores Cancer Center at UC San Diego Health
La Jolla, California · Recruiting
University of Connecticut Health Center
Farmington, Connecticut · Completed
Yale University
New Haven, Connecticut · Recruiting
University of Miami
Miami, Florida · Recruiting
Orlando Health Cancer Institute
Orlando, Florida · Recruiting
Emory University Winship Cancer Institute
Atlanta, Georgia · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Recruiting
Washington University in St Louis
St Louis, Missouri · Recruiting
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey · Recruiting
NYU Langone Health
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
FirstHealth of the Carolinas
Pinehurst, North Carolina · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Oregon Health And Science University
Portland, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Vermont Medical Center
Burlington, Vermont · Recruiting
Chris O'Brien Lifehouse
Camperdown, Australia · Recruiting
Royal Brisbane and Women's Hospital
Herston, Australia · Recruiting
Sir Charles Gairdner Hospital
Nedlands, Australia · Recruiting
Macquarie University
North Ryde, Australia · Recruiting
Royal Melbourne Hospital
Parkville, Australia · Recruiting
Fundacao Pio XII
Barretos, Brazil · Recruiting
Sociedade Beneficente de Senhoras Hospital Sirio Libanes
São Paulo, Brazil · Recruiting
Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
São Paulo, Brazil · Recruiting
Dongguan People s Hospital
Dongguan, China · Recruiting
The First Affiliated Hospital Sun Yat sen University
Guangzhou, China · Recruiting
The Affiliated Cancer Hospital of Shandong First Medical University
Jinan, China · Recruiting
Hopital De La Cavale Blanche
Brest, France · Recruiting
Hopital Nord Marseille
Marseille, France · Recruiting
Hopital Tenon
Paris, France · Recruiting
Institut Curie
Paris, France · Recruiting
CHU Rouen Hopital Charles Nicolle
Rouen, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Prince of Wales Hospital
Shatin, Hong Kong · Recruiting
Antoni van Leeuwenhoek
Amsterdam, Netherlands · Recruiting
Radboud Umcn
Nijmegen, Netherlands · Recruiting
Hosp. Univ. 12 de Octubre
Madrid, Spain · Recruiting
Clinica Univ. de Navarra
Pamplona, Spain · Recruiting
Showing 40 of 45 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.